<DOC>
	<DOCNO>NCT00612651</DOCNO>
	<brief_summary>Objectives : To determine maximum tolerate dose farnesyl transferase inhibitor , SCH 66336 , administer w TEMODAR® . To characterize toxicity associate w combo farnesyl transferase inhibitor , SCH 66336 , &amp; TEMODAR® . To observe patient clinical antitumor response treat combination farnesyl transferase inhibitor , SCH 66336 , &amp; TEMODAR® . To assess pharmacokinetics SCH 66336 patient &amp; enzyme inducing antiepileptic drug .</brief_summary>
	<brief_title>PH I Addition Farnesyl Transferase Inhibitor Temozolomide Pts w Gr 3 &amp; 4 Malignant Gliomas</brief_title>
	<detailed_description>2 separate stratum accrue independently : Stratum1-Patients receive Dilantin , Tegretol / phenobarbital . Stratum2-Patients anti-convulsants Dilantin , Tegretol / phenobarbital / Patients anti-convulsants . Each stratum treat &amp; escalate independent . Temozolomide administer orally dose 150mg/m2 daily 5 day , bedtime , 1st cycle &amp; escalate 200mg/m2 daily 5 day , bedtime subsequent cycle tolerate . Treatment cycle may repeat every 4 week follow dos Temozolomide previous cycle . SCH 66336 administer orally twice day , approximately every 12hrs . Initial dos 125mg BID stratum 1 &amp; 75mg stratum 2 . Treatment cycle may repeat every 4 week follow dose Temozolomide previous cycle . Subjects patient malignant glioma histologically confirm diagnosis , treat previously conventional external beam radiation ( XRT ) &amp; without chemo , &amp; stable disease , recurrence/relapse time enrollment . Approximately 48 subject enrol . Temozolomide well tolerate adult &amp; child common toxicity mild myelosuppression . Other , less likely , potential toxicity include nausea &amp; vomiting , constipation , headache , alopecia , rash , burn sensation skin , esophagitis , pain , diarrhea , lethargy , &amp; hepatotoxicity . Hypersensitivity reaction yet note Temozolomide . As case many anti-cancer drug , Temozolomide may carcinogenic . Rats give Temozolomide develop breast cancer . Significance find human presently know . Significant adverse event observe SCH66336 include vomiting , diarrhea , anorexia , headache , reversible renal toxicity , &amp; hematological toxicity . SCH 66336 , although genotoxic , inhibits rapidly proliferate cell &amp; high dos inhibits spermatogenesis male rat . It clear inhibition spermatogenesis reversible , &amp; patient advised possibility irreversible sterility .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Pts MG histologically confirm diagnosis , treat previously conventional external beam radiation &amp; without chemotherapy , &amp; stable disease , recurrence relapse time enrollment . Age &gt; = 18 year . Patients previous surgical resection ( ) eligible . Interval least 3 week prior surgical resection , 2 week prior radiotherapy , 4 week prior chemotherapy , unless unequivocal evidence tumor progression surgery , radiotherapy , chemotherapy . Karnofsky performance score &gt; = 60 % . Adequate hematologic , renal &amp; liver function demonstrate lab value perform within 14 day , inclusive , prior administration chemotherapy : ANC &gt; = 1500/mm3 Platelet count &gt; = 100,000/mm3 Hemoglobin &gt; = 10 gm/dL BUN serum creatinine &lt; 1.5 time upper limit lab normal Total serum bilirubin &lt; 1.5 time upper limit lab normal SGOT &lt; 2.5 time upper limit lab normal Patients must recover effect major surgery . Patients must life expectancy great 12 week . Patients legal guardian must give write , informed consent . Patients require immediate radiation therapy . Patients recover surgery . Patients neurologically stable 2 week prior study entry . Patients poor medical risk nonmalignant systemic disease well acute infection treat intravenous antibiotic . Frequent vomit medical condition could interfere oral medication intake ( e.g. , partial bowel obstruction ) . Patient &lt; 5 year free another primary malignancy except : primary malignancy currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow . Known HIV positivity AIDSrelated illness . Pregnant nursing woman . Women childbearing potential use effective method contraception . Women childbearing potential must negative serum pregnancy test 72 hour prior administration study drug practice medically approve contraceptive precaution . Men advise use effective method contraception . Patients take immunosuppressive agent prescribed corticosteroid . Patients previously treat farnesyl transferase inhibitor . Patients significant QTc prolongation ( &gt; 500 msec ) evaluate EKG . Patients present prior disease progression TEMODAR . Patients present grade 4 hematologic toxicity grade 3 4 nonhematologic toxicity TEMODAR past .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>GBM</keyword>
	<keyword>Malignant glioma</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Temodar</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>SCH 66336</keyword>
	<keyword>Farnesyl transferase inhibitor</keyword>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>Anaplastic astrocytoma</keyword>
	<keyword>Anaplastic oligodendroglioma</keyword>
	<keyword>Anaplastic oligoastrocytoma</keyword>
</DOC>